News

Tectonic Therapeutic Joins Russell 3000® Index

WATERTOWN, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced that it has been added to the broad-market Russell 3000® Index. Tectonic's addition follows the conclusion of the 2025 Russell US Indexes annual reconstitution and is effective after the open of US equity markets on Monday, June 30, 2025.

06/30/2025

Tectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF in Late-Breaking Presentation at ESC Heart Failure 2025

WATERTOWN, Mass., May 17, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”) today announced the complete results from Part A of the Phase 1b clinical trial of TX45 in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction (“PH-HFpEF”), which are being presented in a late-breaking, oral session at the European Society of Cardiology (ESC) Heart Failure 2025 Congress being held in Belgrade, Serbia. The results include the full cohort of 19 patients in Part A of the Phase 1b trial of TX45, Tectonic's lead asset and a long-acting relaxin therapy. Interim data for 16 patients in the Phase 1b trial was previously reported in a press release on January 30, 2025.

05/17/2025

Profitability

Dividends

Income Statement

Balance Sheet

Cash Flow Statement

Symbol Frequently Asked Questions

Is (TECX) a buy, sell, or hold?

(TECX) can hold. Click on Rating Page for detail.

What is 's stock price?

The price of (TECX) is 21.44 and it was updated on 2025-07-15 13:00:21.

Is (TECX) overvalued or undervalued?

Currently (TECX) is in undervalued.

News

From:

To:

News
Wall Street Analysts See a 258.52% Upside in Tectonic Therapeutic, Inc. (TECX): Can the Stock Really Move This High? The consensus price target hints at a 258.5% upside potential for Tectonic Therapeutic, Inc. (TECX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. Tue, May. 13, 2025
Tectonic Therapeutic Announces First Quarter 2025 Financial Results and Recent Business Highlights WATERTOWN, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced financial results for the first quarter ended March 31, 2025, and provided an overview of recent business highlights. Thu, May. 08, 2025
Tectonic Therapeutic: A Buy On Massive Opportunity Of TX45 In PH HFpEF We initiate a Buy rating on Tectonic Therapeutic due to promising data for TX45. TX45 showed positive interim Phase 1b results, but the APEX Phase 2 trial with 180 patients will be crucial for validating its efficacy and safety. TX2100 targets hereditary hemorrhagic telangiectasia with promising preclinical data, aiming for a Phase 1 launch in late 2025 or early 2026. Wed, Apr. 23, 2025
Tectonic Therapeutic Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights WATERTOWN, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (“GPCRs”), today announced financial results for the fourth quarter and full year ended December 31, 2024, and provided an overview of recent business highlights. Thu, Mar. 20, 2025
Tectonic: Expansion Of TX45 Candidate Possible After Positive Interim Data Positive interim results released from phase 1b study, using TX45 for the treatment of patients with pulmonary hypertension heart failure with preserved ejection fraction. Data from phase 1b study using TX45 for the treatment of patients with pulmonary hypertension heart failure with reduced ejection fraction, expected in 2nd half of 2025. In the 7 major markets, the heart failure market is expected to grow to $33.7 billion in 2032. Wed, Feb. 05, 2025

SEC Filings

SEC Filings
(TECX) - EFFECT SEC Filings 07/09/2025
(TECX) - EFFECT SEC Filings 07/09/2025
(TECX) - S-3 SEC Filings 07/07/2025
(TECX) - POS AM SEC Filings 07/07/2025
(TECX) - 4 SEC Filings 06/24/2025
(TECX) - 424B5 SEC Filings 06/11/2025
(TECX) - 4 SEC Filings 06/11/2025
(TECX) - 8-K - Current report SEC Filings 06/06/2025
(TECX) - 8-K - Current report SEC Filings 05/19/2025
(TECX) - 424B5 SEC Filings 05/19/2025
(TECX) - SCHEDULE 13G/A SEC Filings 05/15/2025
(TECX) - SCHEDULE 13G/A SEC Filings 05/12/2025
(TECX) - 8-K - Current report SEC Filings 05/08/2025
(TECX) - 424B3 SEC Filings 05/08/2025
(TECX) - 10-Q - Quarterly Report SEC Filings 05/08/2025
(TECX) - DEFA14A SEC Filings 04/25/2025
(TECX) - DEF 14A SEC Filings 04/25/2025
(TECX) - ARS SEC Filings 04/25/2025
(TECX) - 4 SEC Filings 04/11/2025
(TECX) - 4 SEC Filings 04/09/2025
(TECX) - SCHEDULE 13D/A SEC Filings 04/07/2025
(TECX) - 4 SEC Filings 04/07/2025
(TECX) - EFFECT SEC Filings 04/03/2025
(TECX) - EFFECT SEC Filings 04/02/2025
(TECX) - UPLOAD SEC Filings 03/31/2025
(TECX) - CORRESP SEC Filings 03/31/2025
(TECX) - POS AM SEC Filings 03/27/2025
(TECX) - S-1 SEC Filings 03/26/2025
(TECX) - S-8 SEC Filings 03/20/2025
(TECX) - 8-K - Current report SEC Filings 03/20/2025
(TECX) - 10-K - Current report SEC Filings 03/20/2025
(TECX) - D SEC Filings 02/14/2025
(TECX) - SCHEDULE 13G/A SEC Filings 02/13/2025
(TECX) - 424B5 SEC Filings 02/12/2025
(TECX) - 424B3 SEC Filings 02/12/2025
(TECX) - SCHEDULE 13G SEC Filings 02/10/2025
(TECX) - SCHEDULE 13D/A SEC Filings 02/10/2025
(TECX) - SCHEDULE 13D/A SEC Filings 02/07/2025
(TECX) - 4 SEC Filings 02/07/2025
(TECX) - 4 SEC Filings 02/06/2025
(TECX) - 8-K - Current report SEC Filings 02/03/2025
(TECX) - 8-K - Current report SEC Filings 01/30/2025
(TECX) - 4 SEC Filings 01/29/2025
(TECX) - 8-K - Current report SEC Filings 01/13/2025
(TECX) - SCHEDULE 13G/A SEC Filings 01/08/2025
(TECX) - 4 SEC Filings 12/11/2024
(TECX) - 4 SEC Filings 12/06/2024
(TECX) - 4 SEC Filings 12/05/2024
(TECX) - SC 13G/A SEC Filings 11/14/2024
(TECX) - 10-Q - Quarterly Report SEC Filings 11/12/2024
(TECX) - 8-K - Current report SEC Filings 11/07/2024
(TECX) - SC 13D/A SEC Filings 10/28/2024
(TECX) - SC 13D/A SEC Filings 10/24/2024
(TECX) - 4 SEC Filings 10/24/2024
(TECX) - SC 13D/A SEC Filings 09/26/2024
(TECX) - 4 SEC Filings 09/26/2024
(TECX) - 8-K - Current report SEC Filings 09/19/2024
(TECX) - S-8 POS SEC Filings 08/27/2024
(TECX) - S-8 SEC Filings 08/21/2024
(TECX) - 8-K - Current report SEC Filings 08/14/2024
(TECX) - 424B3 SEC Filings 08/14/2024
(TECX) - 10-Q - Quarterly Report SEC Filings 08/14/2024
(TECX) - 424B5 SEC Filings 07/31/2024
(TECX) - EFFECT SEC Filings 07/30/2024
(TECX) - 8-K - Current report SEC Filings 07/30/2024
(TECX) - 424B3 SEC Filings 07/30/2024
(TECX) - UPLOAD SEC Filings 07/26/2024
(TECX) - CORRESP SEC Filings 07/26/2024
(TECX) - SC 13G/A SEC Filings 07/22/2024
(TECX) - S-1 SEC Filings 07/19/2024
(TECX) - SC 13G SEC Filings 07/10/2024
(TECX) - 8-K - Current report SEC Filings 07/05/2024
(TECX) - SC 13G SEC Filings 07/01/2024
(TECX) - SC 13D SEC Filings 06/27/2024
(TECX) - SC 13D SEC Filings 06/26/2024
(TECX) - 8-K - Current report SEC Filings 06/26/2024
(TECX) - SC 13D SEC Filings 06/25/2024
(TECX) - 4 SEC Filings 06/25/2024
(TECX) - 4 SEC Filings 06/24/2024
(TECX) - 3 SEC Filings 06/24/2024
(TECX) - 8-K - Current report SEC Filings 06/20/2024
(TECX) - 8-K/A - Current report SEC Filings 06/18/2024
(TECX) - 8-K - Current report SEC Filings 06/14/2024
(TECX) - 8-K - Current report SEC Filings 06/11/2024
(TECX) - 8-K - Current report SEC Filings 06/04/2024
(TECX) - 425 SEC Filings 06/04/2024
(TECX) - 425 SEC Filings 06/03/2024
(TECX) - 425 SEC Filings 05/28/2024
(TECX) - SC 13G/A SEC Filings 05/21/2024
(TECX) - 425 SEC Filings 05/21/2024
(TECX) - 4 SEC Filings 05/15/2024
(TECX) - 3/A SEC Filings 05/15/2024
(TECX) - 3 SEC Filings 05/15/2024
(TECX) - 10-Q - Quarterly Report SEC Filings 05/09/2024
(TECX) - SEC STAFF LETTER SEC Filings 05/07/2024
(TECX) - EFFECT SEC Filings 05/03/2024
(TECX) - 424B3 SEC Filings 05/03/2024
(TECX) - CORRESP SEC Filings 05/02/2024
(TECX) - S-4/A SEC Filings 04/29/2024
(TECX) - CORRESP SEC Filings 04/29/2024
(TECX) - UPLOAD SEC Filings 04/24/2024
(TECX) - SEC STAFF LETTER SEC Filings 04/24/2024
(TECX) - S-4/A SEC Filings 04/15/2024
(TECX) - CORRESP SEC Filings 04/15/2024
(TECX) - UPLOAD SEC Filings 04/08/2024
(TECX) - 425 SEC Filings 04/04/2024
(TECX) - S-4/A SEC Filings 03/26/2024
(TECX) - CORRESP SEC Filings 03/25/2024
(TECX) - 10-K - Current report SEC Filings 03/14/2024
(TECX) - UPLOAD SEC Filings 03/12/2024
(TECX) - SCHEDULE 13G SEC Filings 02/23/2024
(TECX) - SC 13G/A SEC Filings 02/14/2024
(TECX) - SC 13G SEC Filings 02/14/2024
(TECX) - S-4 SEC Filings 02/14/2024
(TECX) - SC 13G/A SEC Filings 02/13/2024
(TECX) - SC 13G/A SEC Filings 02/07/2024
(TECX) - 4 SEC Filings 02/05/2024
(TECX) - 8-K - Current report SEC Filings 01/30/2024
(TECX) - 425 SEC Filings 01/30/2024
(TECX) - SC 13G/A SEC Filings 01/24/2024
(TECX) - 10-Q - Quarterly Report SEC Filings 11/09/2023
(TECX) - RW SEC Filings 11/03/2023
(TECX) - 10-Q - Quarterly Report SEC Filings 08/10/2023
(TECX) - SC 13G SEC Filings 07/24/2023
(TECX) - 144 SEC Filings 07/14/2023
(TECX) - 8-K - Current report SEC Filings 07/12/2023
(TECX) - 4 SEC Filings 07/03/2023
(TECX) - 8-K/A - Current report SEC Filings 06/14/2023
(TECX) - 8-K - Current report SEC Filings 06/13/2023
(TECX) - 4 SEC Filings 06/13/2023
(TECX) - 8-K - Current report SEC Filings 06/12/2023
(TECX) - 8-K - Current report SEC Filings 06/09/2023
(TECX) - 4 SEC Filings 06/08/2023
(TECX) - 144 SEC Filings 06/07/2023
(TECX) - SC 13G SEC Filings 06/06/2023
(TECX) - 144 SEC Filings 06/05/2023
(TECX) - 144 SEC Filings 05/25/2023
(TECX) - 144 SEC Filings 05/24/2023
(TECX) - 8-K - Current report SEC Filings 05/22/2023
(TECX) - 8-K - Current report SEC Filings 05/18/2023
(TECX) - 8-K - Current report SEC Filings 05/11/2023
(TECX) - 10-Q - Quarterly Report SEC Filings 05/11/2023
(TECX) - ARS SEC Filings 05/05/2023
(TECX) - DEF 14A SEC Filings 05/01/2023
(TECX) - 8-K - Current report SEC Filings 05/01/2023
(TECX) - S-8 SEC Filings 03/23/2023
(TECX) - 8-K - Current report SEC Filings 03/23/2023
(TECX) - 10-K - Current report SEC Filings 03/23/2023
(TECX) - 8-K - Current report SEC Filings 02/27/2023
(TECX) - SC 13G SEC Filings 02/17/2023
(TECX) - 4 SEC Filings 02/10/2023
(TECX) - SC 13G/A SEC Filings 02/08/2023
(TECX) - 4 SEC Filings 01/26/2023
(TECX) - SC 13G/A SEC Filings 01/19/2023
(TECX) - 4 SEC Filings 12/28/2022
(TECX) - 4 SEC Filings 12/09/2022
(TECX) - 8-K - Current report SEC Filings 12/07/2022
(TECX) - S-3 SEC Filings 11/08/2022
(TECX) - 8-K - Current report SEC Filings 11/08/2022
(TECX) - 10-Q - Quarterly Report SEC Filings 11/08/2022
(TECX) - 8-K - Current report SEC Filings 10/07/2022
(TECX) - S-8 SEC Filings 08/09/2022
(TECX) - 8-K - Current report SEC Filings 08/09/2022
(TECX) - 10-Q - Quarterly Report SEC Filings 08/09/2022
(TECX) - SC 13G SEC Filings 08/01/2022
(TECX) - SC 13G SEC Filings 07/08/2022
(TECX) - 8-K - Current report SEC Filings 06/29/2022
(TECX) - 3 SEC Filings 06/17/2022
(TECX) - 8-K - Current report SEC Filings 06/10/2022
(TECX) - 4 SEC Filings 06/10/2022
(TECX) - 8-K - Current report SEC Filings 05/24/2022
(TECX) - 8-K - Current report SEC Filings 05/18/2022
(TECX) - 8-K - Current report SEC Filings 05/17/2022
(TECX) - SC 13G/A SEC Filings 05/10/2022
(TECX) - 8-K - Current report SEC Filings 05/10/2022
(TECX) - 10-Q - Quarterly Report SEC Filings 05/10/2022
(TECX) - DEFA14A SEC Filings 04/27/2022
(TECX) - DEF 14A SEC Filings 04/27/2022
(TECX) - S-8 SEC Filings 03/17/2022
(TECX) - 8-K - Current report SEC Filings 03/17/2022
(TECX) - 10-K - Current report SEC Filings 03/17/2022
(TECX) - SC 13G/A SEC Filings 03/09/2022
(TECX) - SC 13G/A SEC Filings 02/14/2022
(TECX) - SC 13G SEC Filings 02/14/2022
(TECX) - SC 13G SEC Filings 02/10/2022
(TECX) - 8-K - Current report SEC Filings 02/09/2022
(TECX) - 4 SEC Filings 02/04/2022
(TECX) - SC 13G/A SEC Filings 02/03/2022
(TECX) - SC 13G/A SEC Filings 01/07/2022
(TECX) - 8-K - Current report SEC Filings 01/07/2022
(TECX) - 8-K - Current report SEC Filings 01/04/2022
(TECX) - 8-K - Current report SEC Filings 11/04/2021
(TECX) - 10-Q - Quarterly Report SEC Filings 11/04/2021
(TECX) - 4 SEC Filings 11/02/2021
(TECX) - 3 SEC Filings 10/27/2021
(TECX) - 8-K - Current report SEC Filings 10/19/2021
(TECX) - 8-K - Current report SEC Filings 08/09/2021
(TECX) - SC 13G SEC Filings 08/05/2021
(TECX) - 8-K - Current report SEC Filings 08/05/2021
(TECX) - 10-Q - Quarterly Report SEC Filings 08/05/2021
(TECX) - 4 SEC Filings 07/08/2021
(TECX) - 8-K - Current report SEC Filings 06/17/2021
(TECX) - 8-K - Current report SEC Filings 06/14/2021
(TECX) - 4 SEC Filings 06/14/2021
(TECX) - 8-K - Current report SEC Filings 05/13/2021
(TECX) - 10-Q - Quarterly Report SEC Filings 05/13/2021
(TECX) - 8-K - Current report SEC Filings 05/03/2021
(TECX) - DEFA14A SEC Filings 04/22/2021
(TECX) - DEF 14A SEC Filings 04/22/2021
(TECX) - 8-K - Current report SEC Filings 03/23/2021
(TECX) - S-8 SEC Filings 03/18/2021
(TECX) - 8-K - Current report SEC Filings 03/18/2021
(TECX) - 10-K - Current report SEC Filings 03/18/2021
(TECX) - 3 SEC Filings 03/10/2021
(TECX) - 4 SEC Filings 02/18/2021
(TECX) - SC 13G/A SEC Filings 02/16/2021
(TECX) - SC 13D/A SEC Filings 02/16/2021
(TECX) - 8-K - Current report SEC Filings 02/08/2021
(TECX) - 4 SEC Filings 02/04/2021
(TECX) - 4 SEC Filings 02/02/2021
(TECX) - SC 13G/A SEC Filings 01/29/2021
(TECX) - 3 SEC Filings 01/22/2021
(TECX) - SC 13G/A SEC Filings 01/20/2021
(TECX) - 8-K - Current report SEC Filings 01/11/2021
(TECX) - 4 SEC Filings 12/28/2020
(TECX) - SC 13G SEC Filings 11/30/2020
(TECX) - 8-K - Current report SEC Filings 11/20/2020
(TECX) - 424B5 SEC Filings 11/20/2020
(TECX) - 424B5 SEC Filings 11/19/2020
(TECX) - 8-K - Current report SEC Filings 11/17/2020
(TECX) - SC 13G/A SEC Filings 11/09/2020
(TECX) - 8-K - Current report SEC Filings 11/05/2020
(TECX) - 10-Q - Quarterly Report SEC Filings 11/05/2020
(TECX) - 8-K - Current report SEC Filings 10/21/2020
(TECX) - 4 SEC Filings 10/21/2020
(TECX) - 3 SEC Filings 10/21/2020
(TECX) - 8-K - Current report SEC Filings 10/06/2020
(TECX) - 8-K - Current report SEC Filings 10/05/2020
(TECX) - S-8 SEC Filings 08/06/2020
(TECX) - 8-K - Current report SEC Filings 08/06/2020
(TECX) - 10-Q - Quarterly Report SEC Filings 08/06/2020
(TECX) - 8-K - Current report SEC Filings 07/06/2020
(TECX) - 8-K - Current report SEC Filings 06/16/2020
(TECX) - 8-K - Current report SEC Filings 06/09/2020
(TECX) - 4 SEC Filings 06/05/2020
(TECX) - 8-K - Current report SEC Filings 05/14/2020
(TECX) - 8-K - Current report SEC Filings 05/13/2020
(TECX) - 8-K - Current report SEC Filings 05/07/2020
(TECX) - 10-Q - Quarterly Report SEC Filings 05/07/2020
(TECX) - DEFA14A SEC Filings 04/22/2020
(TECX) - DEF 14A SEC Filings 04/22/2020
(TECX) - 8-K - Current report SEC Filings 04/03/2020
(TECX) - 8-K - Current report SEC Filings 03/30/2020
(TECX) - S-8 SEC Filings 03/16/2020
(TECX) - 8-K - Current report SEC Filings 03/16/2020
(TECX) - 10-K - Current report SEC Filings 03/16/2020
(TECX) - 4 SEC Filings 03/06/2020
(TECX) - 3 SEC Filings 03/06/2020
(TECX) - 4 SEC Filings 02/18/2020
(TECX) - SC 13G/A SEC Filings 02/14/2020
(TECX) - 5 SEC Filings 02/14/2020
(TECX) - 4 SEC Filings 02/14/2020
(TECX) - 8-K - Current report SEC Filings 02/13/2020
(TECX) - 424B5 SEC Filings 02/13/2020
(TECX) - 424B5 SEC Filings 02/12/2020
(TECX) - 4 SEC Filings 02/11/2020
(TECX) - 8-K - Current report SEC Filings 02/10/2020
(TECX) - SC 13G SEC Filings 02/07/2020
(TECX) - 4 SEC Filings 01/30/2020
(TECX) - SC 13G SEC Filings 01/22/2020
(TECX) - EFFECT SEC Filings 01/14/2020
(TECX) - 8-K - Current report SEC Filings 01/13/2020
(TECX) - CORRESP SEC Filings 01/10/2020
(TECX) - CORRESP SEC Filings 01/02/2020
(TECX) - UPLOAD SEC Filings 12/27/2019
(TECX) - S-8 SEC Filings 12/20/2019
(TECX) - S-3 SEC Filings 12/20/2019
(TECX) - 424B5 SEC Filings 12/20/2019
(TECX) - S-8 SEC Filings 11/12/2019
(TECX) - 8-K - Current report SEC Filings 11/07/2019
(TECX) - 10-Q - Quarterly Report SEC Filings 11/07/2019
(TECX) - 8-K - Current report SEC Filings 10/07/2019
(TECX) - 8-K - Current report SEC Filings 08/08/2019
(TECX) - 10-Q - Quarterly Report SEC Filings 08/08/2019
(TECX) - SC 13D/A SEC Filings 08/06/2019
(TECX) - SC 13D SEC Filings 07/30/2019
(TECX) - 4/A SEC Filings 07/29/2019
(TECX) - 3 SEC Filings 07/29/2019
(TECX) - 4 SEC Filings 07/23/2019
(TECX) - 8-K - Current report SEC Filings 07/17/2019
(TECX) - 424B5 SEC Filings 07/17/2019
(TECX) - 424B5 SEC Filings 07/16/2019
(TECX) - 8-K - Current report SEC Filings 07/15/2019
(TECX) - EFFECT SEC Filings 07/10/2019
(TECX) - CORRESP SEC Filings 07/08/2019
(TECX) - UPLOAD SEC Filings 07/03/2019
(TECX) - S-3 SEC Filings 07/01/2019
(TECX) - 4 SEC Filings 06/13/2019
(TECX) - 8-K - Current report SEC Filings 06/12/2019
(TECX) - SC 13D/A SEC Filings 05/23/2019
(TECX) - 4 SEC Filings 05/22/2019
(TECX) - 8-K - Current report SEC Filings 05/13/2019
(TECX) - 10-Q - Quarterly Report SEC Filings 05/13/2019
(TECX) - 8-K - Current report SEC Filings 04/29/2019
(TECX) - DEFA14A SEC Filings 04/26/2019
(TECX) - DEF 14A SEC Filings 04/26/2019
(TECX) - 4 SEC Filings 04/09/2019
(TECX) - S-8 SEC Filings 03/25/2019
(TECX) - 8-K - Current report SEC Filings 03/25/2019
(TECX) - 10-K - Current report SEC Filings 03/25/2019
(TECX) - 4 SEC Filings 03/07/2019
(TECX) - SC 13G/A SEC Filings 02/14/2019
(TECX) - SC 13G SEC Filings 02/13/2019
(TECX) - 8-K - Current report SEC Filings 02/06/2019
(TECX) - SC 13D SEC Filings 01/25/2019
(TECX) - 8-K - Current report SEC Filings 01/22/2019
(TECX) - 4 SEC Filings 01/18/2019
(TECX) - 3 SEC Filings 01/15/2019
(TECX) - SC 13D/A SEC Filings 01/11/2019
(TECX) - 8-K/A - Current report SEC Filings 01/11/2019
(TECX) - 4 SEC Filings 01/09/2019
(TECX) - 3 SEC Filings 01/09/2019
(TECX) - 8-K - Current report SEC Filings 01/07/2019
(TECX) - 4 SEC Filings 01/04/2019
(TECX) - 3 SEC Filings 01/04/2019
(TECX) - 8-K - Current report SEC Filings 12/21/2018
(TECX) - 4 SEC Filings 12/19/2018
(TECX) - 3 SEC Filings 12/19/2018
(TECX) - 8-K - Current report SEC Filings 11/13/2018
(TECX) - 10-Q - Quarterly Report SEC Filings 11/13/2018
(TECX) - 4 SEC Filings 10/10/2018
(TECX) - 8-K - Current report SEC Filings 10/01/2018
(TECX) - 8-K - Current report SEC Filings 09/24/2018
(TECX) - 8-K - Current report SEC Filings 08/09/2018
(TECX) - 10-Q - Quarterly Report SEC Filings 08/09/2018
(TECX) - SC 13D SEC Filings 07/05/2018
(TECX) - SC 13G SEC Filings 07/02/2018
(TECX) - SC 13G SEC Filings 06/27/2018
(TECX) - 8-K - Current report SEC Filings 06/25/2018
(TECX) - 4 SEC Filings 06/25/2018
(TECX) - 4 SEC Filings 06/22/2018
(TECX) - S-8 SEC Filings 06/21/2018
(TECX) - CT ORDER SEC Filings 06/21/2018
(TECX) - 424B4 SEC Filings 06/21/2018
(TECX) - S-1MEF SEC Filings 06/20/2018
(TECX) - EFFECT SEC Filings 06/20/2018
(TECX) - 3 SEC Filings 06/20/2018
(TECX) - CERT SEC Filings 06/19/2018
(TECX) - S-1/A SEC Filings 06/18/2018
(TECX) - CORRESP SEC Filings 06/18/2018
(TECX) - 8-A12B SEC Filings 06/18/2018
(TECX) - CORRESP SEC Filings 06/15/2018
(TECX) - UPLOAD SEC Filings 06/14/2018
(TECX) - UPLOAD SEC Filings 06/12/2018
(TECX) - S-1/A SEC Filings 06/11/2018
(TECX) - S-1/A SEC Filings 06/01/2018
(TECX) - CORRESP SEC Filings 06/01/2018
(TECX) - S-1 SEC Filings 05/25/2018
(TECX) - CORRESP SEC Filings 05/25/2018
(TECX) - UPLOAD SEC Filings 05/23/2018
(TECX) - DRSLTR SEC Filings 05/11/2018
(TECX) - DRS/A SEC Filings 05/11/2018
(TECX) - UPLOAD SEC Filings 05/07/2018
(TECX) - DRS SEC Filings 04/06/2018
(TECX) - D SEC Filings 02/02/2018
(TECX) - D SEC Filings 08/03/2016

Press Releases

StockPrice Release
Tectonic therapeutic joins russell 3000® index 06/30/2025
Tectonic therapeutic presents complete results for positive phase 1b clinical trial of tx45 in patients with group 2 pulmonary hypertension in hfpef in late-breaking presentation at esc heart failure 2025 05/17/2025
Tectonic therapeutic announces first quarter 2025 financial results and recent business highlights 05/08/2025
Tectonic therapeutic announces fourth quarter and full year 2024 financial results and recent business highlights 03/20/2025
Tectonic announces $185 million private placement 02/03/2025
Tectonic therapeutic announces positive interim data from phase 1b trial for tx45 in patients with group 2 pulmonary hypertension in hfpef 01/30/2025
Tectonic therapeutic to host kol event on the unmet need in group 2 ph-hfpef and tx45 as a potential treatment on thursday, december 12, 2024 12/03/2024
Tectonic therapeutic to present on december 3rd, 2024 at the piper sandler healthcare conference 11/26/2024
Tectonic therapeutic announces positive phase 1a results in aha 2024 presentation for tx45, a long-acting, fc-relaxin fusion protein 11/11/2024
Tectonic therapeutic to present phase 1a data at aha 2024 10/22/2024
Tectonic therapeutic announces favorable phase 1a safety, tolerability and pk/pd results for lead program tx45 09/19/2024
Tectonic therapeutic to participate in september investor conferences 08/20/2024
Tectonic therapeutic announces second quarter 2024 financial results and recent business highlights 08/14/2024

More Headlines

News
Tectonic Announces $185 Million Private Placement WATERTOWN, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), today announced that it has entered into a securities purchase agreement for a private investment in public equity financing (the “PIPE”) that is expected to result in gross proceeds of approximately $185.0 million. 02/03/2025
Tectonic Therapeutic Announces Positive Interim Data from Phase 1b Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF WATERTOWN, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), today announced positive interim data from the Phase 1b acute hemodynamic clinical trial of its lead product candidate, TX45, a long-acting, Fc-relaxin fusion protein. The interim data showed that a single intravenous dose of TX45 resulted in meaningful improvements in both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (“PH-HFpEF”). In the trial, TX45 was well tolerated in patients with PH-HFpEF with no serious or severe adverse events. 01/30/2025
Tectonic Therapeutic: Protein Engineering Platform For GPCRs Tectonic's lead asset, TX45, is a long-acting Fc-relaxin fusion protein to treat group 2 pulmonary hypertension, showing promise in early clinical trials. TX45's extended half-life and monthly dosing address limitations of native relaxin, positioning it as a potential best-in-class therapeutic. With favorable phase 1a data and ongoing phase 1b and 2 trials, Tectonic's TX45 could become a market leader, potentially attracting interest from potential biopharma acquirers. 01/05/2025
Tectonic Therapeutic to Host KOL Event on the Unmet Need in Group 2 PH-HFpEF and TX45 as a Potential Treatment on Thursday, December 12, 2024 WATERTOWN, Mass., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”) a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (“GPCRs”), today announced it will host a virtual key opinion leader (KOL) event on Thursday, December 12, 2024 from 4:00 PM to 6:00 PM ET. To register, click here . 12/03/2024
Tectonic Therapeutic To Present on December 3rd, 2024 at the Piper Sandler Healthcare Conference WATERTOWN, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (Tectonic), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced that Alise Reicin, MD, President and Chief Executive Officer, will present at the Piper Sandler 36th Annual Healthcare Conference being held in New York on December 3-5, 2024. 11/26/2024
Tectonic Therapeutic Announces Positive Phase 1a Results in AHA 2024 Presentation for TX45, a Long-acting, Fc-Relaxin Fusion Protein WATERTOWN, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”) a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (“GPCRs”), today announced detailed results from the Phase 1a clinical trial of its lead asset, TX45, a long-acting, Fc-relaxin fusion protein. The poster will be presented at the American Heart Association (AHA) Scientific Sessions on November 16, 2024 from 3-4pm EST in Chicago, Illinois. Favorable topline results from the TX45 Phase 1a clinical trial were announced on September 19, 2024, along with the dose selection for the TX45 APEX Phase 2 trial that is currently underway in patients with PH-HFpEF. 11/11/2024
Tectonic Therapeutic to Present Phase 1a Data at AHA 2024 American Heart Association (AHA) poster to be presented on November 16, 2024 American Heart Association (AHA) poster to be presented on November 16, 2024 10/22/2024
Tectonic Therapeutic: Interesting CV Disease Drug Developer Tectonic Therapeutic's lead candidate TX45 showed positive phase 1 results for Group 2 Pulmonary Hypertension, driving the stock up over 100% in September. TX45 is an Fc-relaxin fusion molecule targeting the RXFP1 receptor, offering potential therapeutic benefits for hypertension and heart failure with preserved ejection fraction (HFpEF). Tectonic has a solid financial position with a market cap of $551mn, $185mn in cash reserves, and a cash runway extending into 2027. 10/20/2024
Tectonic Therapeutic Announces Favorable Phase 1a Safety, Tolerability and PK/PD Results for Lead Program TX45 TX45 was well-tolerated with no observed immunogenicity, and demonstrated a favorable PK/PD relationship which was used to identify doses for the Phase 2 clinical trial 09/19/2024
TECX Stock Earnings: Tectonic Therapeutic Misses EPS for Q2 2024 Tectonic Therapeutic (NASDAQ: TECX ) just reported results for the second quarter of 2024. Tectonic Therapeutic reported earnings per share of -$4.34. 08/24/2024
Tectonic Therapeutic to Participate in September Investor Conferences WATERTOWN, Mass., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (Tectonic), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced that company management will present at the 2024 Wells Fargo Healthcare Conference being held in Boston on September 4-6, 2024 and participate in the Morgan Stanley 22nd Annual Global Healthcare Conference being held in New York on September 4-6, 2024. 08/20/2024
Tectonic Therapeutic Announces Second Quarter 2024 Financial Results and Recent Business Highlights TX45 advances into Phase 2 clinical trial for patients with Group 2 PH-HFpEF with first site activated and screening open in August 2024 Received U.S. Investigational New Drug (IND) clearance for lead program, TX45 in July 2024 Completed reverse merger with AVROBIO in June 2024, including concurrent private placement of $130.7 million Cash and cash equivalents were $185.1 million as of June 30, 2024, prior to the payment of accrued transaction and related expenses of approximately $14.4 million, are expected to provide cash runway into mid-2027 WATERTOWN, Mass., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”, or “the Company”), a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced its financial results for the second quarter ending June 30, 2024, and provided an overview of recent business highlights. 08/14/2024

Unlock

TECX Ratings Summary

TECX Quant Ranking